IRVINE, Calif., June 29, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit
against Roche Holding AG (“Roche Holding” or the “Company”) (Other OTC:RHHBY). Investors who purchased or otherwise acquired shares
from March 2, 2017 through June 5, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm in advance of the
August 7, 2017 lead plaintiff motion deadline.
If you purchased shares of Roche Holding during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP,
18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at
joon@khanglaw.com.
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney.
You may also choose to take no action and remain a passive class member.
According to the Complaint, throughout the Class Period, Roche Holding issued materially false and misleading statements and/or
failed to disclose material information, specifically that the combination of the Company’s breast cancer drug, Perjeta, and its
older treatment, Herceptin, is only marginally more effective than Herceptin alone in preventing breast cancer, and has a higher
rate of side effects. When this information reached the public, shares of Roche Holding lowered in value materially, causing
investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone at (949) 419-3834,
or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 joon@khanglaw.com
